How are bisphosphonates used today in breast cancer clinical practice? Journal Article
| Author: | Van Poznak, C. |
| Article Title: | How are bisphosphonates used today in breast cancer clinical practice? |
| Abstract: | In the United States there are approximately 100,000 women living with metastatic breast cancer. Bone is the most common site of breast cancer metastases and it is estimated that up to 85% of patients dying from this disease have developed osseous involvement. Skeletal metastases are often associated with dangerous and painful events such as fractures, spinal cord compression, and hypercalcemia. Bisphosphonates, through their inhibition of osteoclastic bone-resorptive activity, offer a rational approach to the management of bone metastases as they are of proven efficacy in reducing skeletal-related events. Bisphosphonates are also effective in the prevention and treatment of hypercalcemia and osteoporosis. The American Society of Clinical Oncology guidelines are instructive regarding patient selection for bisphosphonate therapy; however, a number of unanswered questions remain on how best to utilize this therapeutic intervention. This article reviews the role of bisphosphonates in the care of patients with breast cancer. Copyright © 2001 by W.B. Sounders Company. |
| Keywords: | bone neoplasms; fracture; androgen; clinical trial; drug efficacy; drug safety; patient selection; bone metastasis; conference paper; antineoplastic agent; quality of life; breast cancer; gastrointestinal symptom; estrogen; bisphosphonic acid derivative; calcium; bone pain; hypercalcemia; peptide; breast neoplasms; ovary insufficiency; collagen type 1; alkaline phosphatase; cytokine; vitamin d; spinal cord compression; tamoxifen; osteoporosis; gonadorelin derivative; estrogen receptor; hormone; growth factor; diphosphonates; alendronic acid; antiestrogen; zoledronic acid; analgesic agent; pyridine derivative; raloxifene; bone resorption; bone turnover; bone atrophy; gestagen; pamidronic acid; clodronic acid; ibandronic acid; osteomalacia; risedronic acid; etidronic acid; bone mineral; tiludronic acid; humans; human; female; priority journal |
| Journal Title: | Seminars in Oncology |
| Volume: | 28 |
| Issue: | Suppl. 11 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2001-08-01 |
| Start Page: | 69 |
| End Page: | 74 |
| Language: | English |
| PUBMED: | 11544580 |
| PROVIDER: | scopus |
| DOI: | 10.1016/S0093-7754(01)90236-2 |
| DOI/URL: | |
| Notes: | Presented at the Roundtable Discussion Meeting Update on the Role of Bisphosphonates in Metastases; 2000 Dec 5; San Antonio, TX -- Source: Scopus |
